Understanding how MUC5B contributes to lung injury and fibrosis
Diversity Supplement to Mechanisms Regulating Lung Injury and Early Lung Fibrosis
This study is looking at how a molecule called MUC5B makes lungs more prone to damage, which can lead to conditions like idiopathic pulmonary fibrosis (IPF), and it aims to find ways to help prevent or treat these lung issues for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11012571 on NIH RePORTER |
What this research studies
This research investigates the role of a specific molecule called MUC5B in making the lungs vulnerable to injury and how this vulnerability can lead to conditions like idiopathic pulmonary fibrosis (IPF). The study aims to identify the mechanisms by which MUC5B affects lung cells and contributes to persistent lung damage and fibrosis. By examining the interactions between lung epithelial cells and fibroblasts, the research seeks to uncover the factors that trigger and exacerbate lung injury. Patients may benefit from insights gained into how to prevent or treat lung conditions associated with MUC5B.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with genetic variants related to MUC5B and those experiencing early signs of lung injury.
Not a fit: Patients with established lung fibrosis or those without the genetic predisposition related to MUC5B may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating lung fibrosis in patients at risk.
How similar studies have performed: Previous research has shown promising results in understanding the role of genetic factors in lung diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Schwartz, David Albert — University of Colorado Denver
- Study coordinator: Schwartz, David Albert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.